Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

PHASE3TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

December 17, 2014

Primary Completion Date

December 12, 2016

Study Completion Date

February 15, 2017

Conditions
Long QT Syndrome Type 3
Interventions
DRUG

Eleclazine

Tablets administered orally

DRUG

Eleclazine placebo

Tablets administered orally

Trial Locations (12)

10016

NYU Langone Medical Center, New York

14642

University of Rochester Medical Center, Rochester

27100

Fondazione Salvatore Maugeri IRCCS, Pavia

44093

L'institut Du Thorax Nantes, Nantes

55905

Mayo Clinic Rochester, Rochester

75877

Groupe Hospitalier Bichat Claude Bernard, Paris

80336

LMU Klinikum der Universität München, München

97410

CHU Réunion Sud, Saint-Pierre

B3H 3A7

Nova Scotia Health Authority, Halifax

Unknown

Tel Aviv Sourasky Medical Center, Tel Aviv

1105 AZ

Academisch Medisch Centrum Amsterdam, Amsterdam

EC1M 6BQ

Barts and The London School of Medicine and Dentistry, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY